Trials / Completed
CompletedNCT02401945
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect of Intravitreal Injections of DE-120 as Monotherapy and With a Single Eylea® Injection in Subjects With Treatment-Naive Exudative Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Santen Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-120 | |
| DRUG | Aflibercept |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-06-22
- Completion
- 2016-10-31
- First posted
- 2015-03-30
- Last updated
- 2018-04-18
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02401945. Inclusion in this directory is not an endorsement.